Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPP5A | Q14642 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | AOC2 | O75106 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23012533 | 0.86 | INPP5A (0.44) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL1647665 | 0.86 | INPP5A (0.44) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL23160212 | 0.86 | INPP5A (0.44) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL6962289 | 0.85 | INPP5A (0.42) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL7931443 | 0.82 | — | — | |
| SCHEMBL9099973 | 0.82 | INPP5A (0.62) | INPP5A | |
| Hydrochloric Acid SCHEMBL27888894 | 0.79 | — | — | |
| SCHEMBL965787 | 0.79 | — | — | |
| SCHEMBL27984591 | 0.78 | INPP5A (0.38) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL2573293 | 0.77 | APP (0.34) | INPP5ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930958-A | Anion exchange polymer and preparation method thereof, and preparation method of anion exchange membrane | 惠州亿纬氢能有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-121045118-A | Synthesis method of tetrahydropyran-4-sulfonyl chloride | 常熟泓德生物科技有限公司 | 2025-12-02 | — | — | CN | disclosed |
| CN-116507333-B | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119930958-A | Anion exchange polymer and preparation method thereof, and preparation method of anion exchange membrane | 惠州亿纬氢能有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119775277-A | Compounds as modulators of LRRK2, NUAK1 and/or TYK2 kinases for the treatment of, for example, autoimmune diseases | 原真股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| CN-119562952-A | KIF18A inhibitors | 山东轩竹医药科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119330963-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119118999-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118955477-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2022092141-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | 塩野義製薬株式会社 | 2022-05-05 | — | — | WO | disclosed |
| CN-113227074-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods | 凌科药业(杭州)有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-107849017-B | 1,1, 1-trifluoro-3-hydroxypropan-2-ylcarbamate derivatives and 1,1, 1-trifluoro-4-hydroxybutyl-2-ylcarbamate derivatives as MAGL inhibitors | 辉瑞公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112409334-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-112174935-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-111433208-A | Pyrrolo (pyrazolo) pyrimidine derivatives as L RRK2 inhibitors | 奥斯考泰克公司 | 2020-07-17 | — | — | CN | disclosed |
| US-10233176-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2019-03-19 | — | — | US | disclosed |
| WO-2018103060-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| US-20170022189-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2017-01-26 | — | — | US | disclosed |
| EP-2141163-A1 | Substituted thiazolidinones, their production and utilisation as medicine | Bayer Schering Pharma AG (DE) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233176-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | INPP5A 2868/4885CNR2 2982/4885CNR1 3339/4885 |
| US-20170022189-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K6, MAP3K5, MERTK | INPP5A 2868/4885CNR2 2982/4885CNR1 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.